Literature DB >> 33603891

Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area.

Andra-Iulia Suceveanu1, Ioan Sergiu Micu1, Gabriela-Izabela Baltatescu2, Lucian Cristian Petcu3, Nicolae Dobrin2, Costel Brinzan4, Cornelia Nitipir5, Laura Mazilu6, Florin Botea7, Vlad Herlea8, Felix Voinea9, Adrian Paul Suceveanu1.   

Abstract

Epidemiological data regarding hepatocellular carcinoma (HCC) report unsatisfactory morbimortality rates despite the global efforts to decrease the incidence and prolong patient survival. Current guidelines lack diagnostic biomarkers to better characterize patients with HCC. We aimed to validate the overexpression of Survivin-1, tumor-associated glyocoprotein 72 (Tag-72), and HECT and RLD domain containing E3 ubiquitin protein ligase 5 (HERC5) as tissue biomarkers for HCC characterization in patients from our geographical area and to standardize a local biomarker panel to be introduced in the current management guideline. Thirty samples of histologically confirmed HCC were compared to an equal number of samples of benign tumors in terms of Survivin-1, TAG-72, and HERC5 overexpression. Student's t-test, Mann-Whitney U test and Chi-square test were used to find differences between the two studied groups and to compare the categorical variables. The discriminative power of Survivin-1, Tag-72, and HERC5 overexpression was assessed using ROC curves. The multivariate linear regression analysis revealed that Survivin, Tag-72, and HERC5 were significantly overexpressed in older male patients, with α-fetoprotein (AFP) >200 ng/dl, low serum albumin, as well as in patients with imaging features of portal thrombosis and ascites. The diagnostic performance of Survivin-1, Tag-72 and HERC5 tissue biomarkers for HCC characterization was superior to that of the gold-standard AFP. Our study results validate the overexpression of Survivin-1, Tag-72, and HERC5 as tissue biomarkers for HCC characterization in patients from our geographical region and could be standardized in the current HCC management guideline.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  HERC5; Survivin-1; Tag-72; hepatocellular carcinoma; immunohistochemistry; overexpression

Year:  2021        PMID: 33603891      PMCID: PMC7851649          DOI: 10.3892/etm.2021.9715

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  24 in total

Review 1.  When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry--the red, brown, and blue technique.

Authors:  J A Ramos-Vara; M A Miller
Journal:  Vet Pathol       Date:  2013-10-15       Impact factor: 2.221

Review 2.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

3.  HCC with low- and normal-serum alpha-fetoprotein levels.

Authors:  Brian I Carr; Hikmet Akkiz; Oguz Üsküdar; Kendal Yalçın; Vito Guerra; Sedef Kuran; Ümit Karaoğullarından; Engin Altıntaş; Ayşegül Özakyol; Salih Tokmak; Tuğsan Ballı; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Anıl Delik; Burcu Arslan; Figen Doran; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

4.  Neoangiogenesis. Assessment in Esophageal Adenocarcinomas.

Authors:  Valeriu Ardeleanu; Laurian Francu; Costinela Georgescu
Journal:  Indian J Surg       Date:  2014-05-10       Impact factor: 0.656

Review 5.  Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2017-12-20       Impact factor: 2.935

6.  Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women.

Authors:  F Donato; A Tagger; U Gelatti; G Parrinello; P Boffetta; A Albertini; A Decarli; P Trevisi; M L Ribero; C Martelli; S Porru; G Nardi
Journal:  Am J Epidemiol       Date:  2002-02-15       Impact factor: 4.897

7.  Detection of serum gastric cancer-associated MG7-Ag from gastric cancer patients using a sensitive and convenient ELISA method.

Authors:  Bin Jin; Xin Wang; Yan Jin; Wensen Xia; Bei Chen; Lin Liu; Zheng Chen; Liu Hong; Wenqi Du; Kun Yan; Honghong Wang; Donghong Yuan; Xiaoli Hui; Li He; Faming Zhang; Yunping Zhao; Kaichun Wu; Daiming Fan
Journal:  Cancer Invest       Date:  2009-02       Impact factor: 2.176

8.  Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?

Authors:  Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Cantarini; Carmela Cursaro; Gianludovico Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

Review 9.  Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors.

Authors:  Aileen Baecker; Xing Liu; Carlo La Vecchia; Zuo-Feng Zhang
Journal:  Eur J Cancer Prev       Date:  2018-05       Impact factor: 2.497

10.  Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance.

Authors:  Sachiko Nishimoto; Daiju Fukuda; Yasutomi Higashikuni; Kimie Tanaka; Yoichiro Hirata; Chie Murata; Joo-Ri Kim-Kaneyama; Fukiko Sato; Masahiro Bando; Shusuke Yagi; Takeshi Soeki; Tetsuya Hayashi; Issei Imoto; Hiroshi Sakaue; Michio Shimabukuro; Masataka Sata
Journal:  Sci Adv       Date:  2016-03-25       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.